Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Oncternal Therapeutics

07/05/2021 12:11

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 12 cents​​ per share for the quarter ended
in March. The mean expectation of four analysts for the quarter
was for a loss of 10 cents per share.
* Revenue rose 29.4% to $748.00 thousand from a year ago​; 
analysts expected $1.11 million.
* The mean earnings estimate of analysts had risen by about 9.1%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Oncternal Therapeutics Inc shares had fallen by 34.5% this
quarter and gained 11.2% so far this year.
* Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $16.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 7 at 11:11 a.m. GMT. ​All
figures in US Dollars.​